Nuvelo has appointed Hana Moran as vice president of regulatory affairs and quality assurance. Moran comes to Nuvelo from Lipid Sciences, where she was vice president of regulatory affairs and quality assurance. Before that she held senior management positions at BioMedicines and SangStat Medical, Nuvelo said.
From 1983 to 1994, Moran served in various regulatory affairs and quality-assurance roles at companies including Athena Neurosciences, Fujisawa Pharmaceutical, Boehringer-Ingelheim, and G.D. Searle, Nuvelo said.
PTC Therapeutics has appointed H. Lee Sweeney to its scientific advisory board. Sweeney is professor and chairman of physiology at the University of Pennsylvania School of Medicine. He is also a member of the board of scientific counselors of the National Institute of Arthritis, Musculoskeletal and Skin Diseases of the National Institute of Health; and the scientific director for the Parent Project Muscular Dystrophy organization and on the Translational Research Advisory Committee for the Muscular Dystrophy Association.
Shane Grey has been appointed to the scientific advisory board of CombiMatrix, the company’s parent, Acacia Research, said announced week.
Grey is an assistant professor of surgery at Harvard Medical School, and has experience in viral delivery of therapeutic nucleic acids, the company said. CombiMatrix, of Squolamie, Wash., has recently launched an siRNA drug-discovery initiative.
Grey, an Australian, did postdoctoral research at the Sandoz Center for Immunobiology in Boston, according to PTC. He plans to move his research to the Garvan Institute of Medical Research in Sydney in the coming year.
Monica Tamborini has been appointed chief financial officer and chief operations officer of DNA Print Genomics, of Sarasota, Fla., the company said last week.
Tamborini was previously CFO of Calix and subsidiary Pharm-eco Laboratories between 1992 and 2001, and was also CFO of Universal Pharma Technologies, a joint venture between Pharm-eco Laboratories and Universal Oil Processors, DNA Print said.
Robert Johnson has been named president and chief operating officer of Spectral Genomics.
Johnson comes to the Houston-based microarray company from VitaGen, a cell therepy, where he was chief operating officer and chief scientific officer at. Prior to that, he was senior research director of the gene therapy business unit at Baxter Healthcare, where he worked for 18 years.